Table 3 Main adverse events for 1st, 2ndand 3rd
Treatment, n(%) | |||
|---|---|---|---|
Adverse events | 1 (n = 129) | 2 (n = 50) | 3 (n = 41) |
Lipoatrophy | 26 (20) | 11 (22) | 5 (12) |
Rash | 13 (10) | 0 (0) | 11 (27) |
Anaemia | 10 (8) | 10 (20) | 4 (10) |
Neuropathy | 5 (4) | 4 (8) | 1 (2) |
Metabolic disturbance | 6 (6) | 0 (0) | 0 (0) |